Tirzepatide for Obesity Treatment and Diabetes Prevention
Abstract
- This phase 3, double-blind, randomized controlled trial followed 1032 participants with obesity and prediabetes for 3 years as part of the SURMOUNT-1 study. Participants were assigned to weekly doses of tirzepatide (5 mg, 10 mg, or 15 mg) or placebo. At week 176, mean weight loss reached up to 19.7% with the 15-mg dose, compared to just 1.3% with placebo. The onset of type 2 diabetes was significantly reduced among those receiving tirzepatide (1.3% vs. 13.3%; hazard ratio 0.07, P<0.001). Even after a 17-week off-treatment period, benefits largely persisted. The study also demonstrated improvements in blood pressure, lipid profiles, insulin sensitivity, and health-related quality of life. Gastrointestinal events were the most common side effects, generally mild and transient. The findings support tirzepatide as an effective long-term therapy for obesity and diabetes prevention.
Keywords:
tirzepatide
obesity
prediabetes
type 2 diabetes
weight loss
GIP/GLP-1 agonist
long-term efficacy
randomized controlled trial
Article Document
1 / 1
100%